Kidney cancers are classified based on the type of cell where they start and how the cancer cells look under a microscope. Knowing the type of kidney cancer can help your healthcare team predict how the cancer may behave and which kidney cancer treatments may work best.
When most people talk about kidney cancer, they’re referring to renal cell carcinoma (RCC) — the most common type. But RCC includes several subtypes, and there are also other, less common cancers that can develop in the kidneys. Moreover, some people develop kidney tumors that are benign (noncancerous), which still require monitoring and possibly treatment.
In this article, we’ll walk through the most common RCC subtypes as well as other kidney cancers. Understanding the specifics of your diagnosis can help you feel more prepared and have better conversations with your doctor about your treatment options.
Renal cell carcinoma is the most common type of kidney cancer, accounting for 80 percent to 85 percent of all kidney cancer cases. RCC begins in the cells that line the renal tubules — tiny, hollow structures in the kidney that help filter the blood, return useful substances to the body, and remove waste as urine. These tubules are located in both the renal cortex (outer layer) and medulla (inner layer) of the kidney.
There are more than a dozen subtypes of RCC. A pathologist (a doctor who specializes in diagnosing health conditions by examining tissues) determines the specific subtype by studying the cancer’s appearance. This process is part of a field called tumor histology.
There are two main subtypes of RCC: clear cell RCC and non-clear cell RCC.
Clear cell RCC makes up about 70 percent of RCC cases. Under a microscope, the cancer cells look pale or clear, which is where the name comes from. Most people with clear cell RCC don’t notice symptoms, especially in early stages. Compared to other subtypes, this form often grows faster and is more likely to metastasize (spread) to other parts of the body.
Treatment for early-stage clear cell RCC typically involves surgery, such as:
Other treatment options include:
Subtypes of RCC that aren’t classified as clear cell RCC are known as non-clear cell RCC. Papillary RCC and chromophobe RCC are the most common subtypes of non-clear cell RCC, but this group also includes several rare subtypes.
These rarer forms include:
Specific symptoms and treatments may differ based on the subtype.
About 5 percent to 10 percent of people diagnosed with RCC have chromophobe RCC. Under a microscope, chromophobe RCC cancer cells are larger and darker than the pale, clear cells seen in clear cell RCC.
Chromophobe RCC tends to be diagnosed at an earlier stage and may be more common in younger people. Additionally, in females, it’s more common than other types of kidney cancer, according to Critical Reviews in Oncology/Hematology.
In general, kidney cancer is typically more common in men than women, according to the American Cancer Society.
Chromophobe RCC is often associated with a good prognosis (outlook) because it’s usually less aggressive than clear cell RCC. However, this type of RCC may not respond to some kidney cancer treatments, such as immunotherapy.
Transitional cell carcinoma (TCC) is a non-clear cell type of kidney cancer, and it’s the second most common type after RCC. This type accounts for about 8 percent of all kidney cancers.
Also known as urothelial carcinoma, TCC develops when transitional cells (the cells that line parts of the kidney and urinary tract) begin to grow out of control. In the kidney, these cells are found in the renal pelvis, the area where the kidney connects to the ureter (the tube that carries urine to the bladder).
Because of where it starts, TCC of the kidney often resembles bladder cancer more than other kidney cancers.
People who have had bladder cancer or who have other kidney cancer risk factors, such as smoking or exposure to certain chemicals, may be at a higher risk of developing TCC. Symptoms of TCC are often similar to those of other kidney cancers and may include:
Treatment options for transitional cell carcinoma may include:
Renal sarcomas are a rare type of kidney tumor, making up less than 1 percent of all kidney cancers. Sarcomas are cancers that begin in connective tissues, such as muscles, blood vessels, nerves, or fatty tissue. When this kind of cancer starts in the kidney’s connective tissue, it’s called a renal sarcoma.
In some cases, other kidney cancers, including RCC, can develop sarcomatoid features. This means the cancer cells don’t originate in connective tissue, but under a microscope, they resemble sarcomas.
Cancers with sarcomatoid features tend to be more aggressive, grow quickly, and are more likely to spread to other parts of the body.
Treatment for renal sarcoma often involves a combination of surgery, chemotherapy, and radiation. Even after treatment, renal sarcomas have a high risk of recurrence (returning), which makes follow-up care and monitoring especially important.
Not all kidney tumors are cancerous. Benign kidney tumors can grow in the kidney and cause complications by taking up space or pressing on nearby structures.
Examples of benign kidney tumors include:
Treatment for benign kidney tumors usually involves removing or destroying the kidney tumor with surgery or radiofrequency ablation. In some cases, active surveillance (regular monitoring with imaging tests) may be recommended if the tumor isn’t causing problems.
Get updates directly to your inbox.
My 70 year old spouse has had Clear Cell RCC for 4 years 8 months, it has spread to the hip and the cervical spine, What is life expectancy?
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
All I was told was it was stage 2 kidney cancer and they removed my left kidney 2 weeks after I was first seen at er for pain in my side insurance was canceled when I was fired 2 weeks after… read more
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.